Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Hill Dermaceuticals, Inc.

Hill Dermaceuticals, Inc. Recalls

All product recalls associated with Hill Dermaceuticals, Inc..

Get alerts for this brand

Recall Summary

Total Recalls

1000

Past Year

304

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 3941–3960 of 4747 recalls

Fluocinolone Acetonide Body Oil (Hill Dermaceuticals) – Low Potency (2014)

Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.

Class IIILow

FDAJan 31, 2014Nationwide• Hill Dermaceuticals, Inc.

Fluocinolone Acetonide Topical Oil (Hill Dermaceuticals) – Low Potency (2014)

Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.

Class IIILow

FDAJan 31, 2014Nationwide• Hill Dermaceuticals, Inc.

DermOtic Oil (Hill Dermaceuticals) – Low Potency (2014)

Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.

1...196 197198199 200...238

Page 198 of 238Next

Class IIILow

FDAJan 31, 2014Nationwide• Hill Dermaceuticals, Inc.

DermOtic Ear Drops (Hill Dermaceuticals) – Low Potency (2014)

Subpotent Drug: The active ingredient, fluocinolone acetonide, was found to be subpotent during the firm's routine testing.

Class IIILow

FDAJan 31, 2014Nationwide• Hill Dermaceuticals, Inc.

Triamcinolone Cream (Fougera) – Labeling Error (2014)

Labeling: Label Error on Declared Strength: There is a misprint on the end flap which read 01% rather than 0.1%.

Class IIILow

FDAJan 29, 2014Nationwide• Fougera Pharmaceuticals Inc.

Oxcarbazepine Tablets (Caraco) – Broken Tablets (2014)

Failed Tablet Specifications: Broken Tablets Present.

Class IIModerate

FDAJan 29, 2014Nationwide• Caraco Pharmaceutical Laboratories Ltd.

Remote Control Helicopters (Horizon Hobby) – Injury Hazard (2014)

The recall involves Blade 500 X BNF and Blade 500 3D BNF and RTF Remote Controlled Model Helicopters with model numbers BLH 1800, BLH 1800M1, BLH 1850, and BLH 4080. The helicopters are about 33.5 inches long and 11.8 inches tall and weigh about 4 lbs. The canopy of the 500 X has the "500 X" logo on each side. The canopy of the 500 3D has the "500 3D" logo on each side. The tail rotor grip for each model is a black plastic holder that holds the tail rotor blades of the helicopter in place. The grips are approximately 1 ¼ inches tall and ½ inch wide.

CPSCJan 28, 2014Nationwide• Shenzen Shen's Tongchuang Aeronautic Model Co., Ltd. of China

Metformin HCl Extended-Release (Caraco) – Foreign Tablet Contamination (2014)

Presence of Foreign Tablet; customer complaint of some tablets of Gabapentin found in a bottle of Metformin HCl ER

Class IIModerate

FDAJan 28, 2014Nationwide• Caraco Pharmaceutical Laboratories, Ltd.

Suprax Cefixime Suspension (Lupin) – Impurity Specification Failure (2014)

Failed Impurities/Degradation Specifications: Product did not meet specification in total impurities at the 9-month stability station.

Class IIILow

FDAJan 27, 2014Nationwide• Lupin Pharmaceuticals Inc.

Suprax Cefixime Suspension (Lupin) – Impurity Specification Failure (2014)

Failed Impurities/Degradation Specifications: Product did not meet specification in total impurities at the 9-month stability station.

Class IIILow

FDAJan 27, 2014Nationwide• Lupin Pharmaceuticals Inc.

Ethambutol Tablets (Teva) – CGMP Manufacturing Deviation (2014)

CGMP Deviations: Ethambutol Hydrochloride Tablets, USP, 400 mg were manufactured using unapproved material: the incorrect gelatin excipient than specified in the product formulation.

Class IIModerate

FDAJan 24, 2014Nationwide• Teva Pharmaceuticals USA

Dextroamphetamine Tablets (Teva) – CGMP Manufacturing Deviation (2014)

CGMP Deviations: Dextroamphetamine Saccharate, Amphetamine Asparate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, CII, 10 mg were manufactured using unapproved material: the finished product was not properly quarantined as rejected due to inadequate cleaning of equipment.

Class IIModerate

FDAJan 24, 2014Nationwide• Teva Pharmaceuticals USA

Hydroxyzine Pamoate Capsules (Teva) – CGMP Manufacturing Deviation (2014)

CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 25 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.

Class IIModerate

FDAJan 24, 2014Nationwide• Teva Pharmaceuticals USA

Hydroxyzine Pamoate Capsules (Teva) – CGMP Manufacturing Deviation (2014)

CGMP Deviations: Hydroxyzine Pamoate Capsules, USP, 100 mg were manufactured using an unapproved material: API was incorrectly released for use in manufacturing.

Class IIModerate

FDAJan 24, 2014Nationwide• Teva Pharmaceuticals USA

Chocolate Drink Mix (Winn-Dixie) – Incorrect Formula (2014)

Undeclared Allergen

Product may contain incorrect formula mixture, which could result in an undeclared milk allergen.

Class IHigh

FDAJan 20, 2014FL• Winn-Dixie Logistics, Inc.

Levothyroxine Sodium Tablets (Mylan) – subpotent medication (2014)

Subpotent Drug: Assay results obtained during stability testing for Levothyroxine Sodium Tablets, USP were below specification.

Class IIModerate

FDAJan 14, 2014Nationwide• Mylan Pharmaceuticals Inc.

Hydralazine HCL 25mg Tablets (Teva) – Impurity Risk (2013)

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Class IIModerate

FDADec 18, 2013Nationwide• Teva Pharmaceuticals USA

Hydralazine HCL 50mg Tablets (Teva) – Impurity Risk (2013)

Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Class IIModerate

FDADec 18, 2013Nationwide• Teva Pharmaceuticals USA

VoLumen Barium Suspension (Bracco) – Preservative Issue (2013)

Failed Stability Testing: This product is below specification for preservative content.

Class IIILow

FDADec 16, 2013Nationwide• Bracco Diagnostics Inc

Cetirizine Hydrochloride Syrup (Qualitest) – Impurity Found (2013)

Failed impurities/degradation specifications; out of specification for the known impurity 4-chlorobenzophenone.

Class IIILow

FDADec 16, 2013Nationwide• Qualitest Pharmaceuticals